Autres langues Veru Inc.

Actions

VERU

US92536C1036

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 10/06/2024			Varia. 5j.	Varia. 1 janv.
0,9017 ^USD	-1,80 %		-10,72 %	+25,24 %

22/05	Veru Inc. présentera une mise à jour du programme clinique de phase 2B d'Enobosarm visant à augmenter la perte de graisse et à éviter la perte de muscle en combinaison avec des médicaments GLP-1 pour la perte de poids lors de la Jefferies Global Healthcare Conference	CI
14/05	VERU INC. : B. Riley persiste à l'achat	ZM

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Veru to Present at the American Diabetes Association's 84th Scientific Sessions	10/06
Veru to Present at the Jefferies Global Healthcare Conference	22/05
Veru Inc. to Present an Update of Veru's Phase 2B Clinical Program of Enobosarm to Augment Fat Loss and to Avoid Muscle Loss When Combined with GLP-1 Drugs for Weight Loss At the Jefferies Global Healthcare Conference	22/05
Veru Announces Steven B. Heymsfield M.D. as the Principal Investigator for its Enobosarm Phase 2b Clinical Trial for High Quality Weight Loss	15/05
Veru Announces Mitchell Steiner as Keynote Speaker at Biomed Israel 2024: The 22nd National Life Science & Technology Week	14/05
Veru Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2024	08/05
Earnings Flash (VERU) VERU Posts Q2 Revenue $4.1M	08/05
Veru Reports Fiscal 2024 Second Quarter Financial Results and Progress of its Enobosarm High Quality Weight Loss Clinical Program	08/05
Veru to Present at the GLP-1 Based Therapeutics Summit	02/05
Veru to Report Fiscal 2024 Second Quarter Financial Results on May 8, 2024	01/05
Veru : Corporate Presentation, May 2024	30/04
Veru Enrolls First Patients in Phase 2b Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss	30/04
Veru Inc. Enrolls First Patients in Phase 2b Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss	30/04
Veru to Present at the American Association of Clinical Endocrinology (AACE) 2024 Annual Meeting on May 9-11	25/04
Veru Announces Date of 2024 Annual Meeting of Shareholders	01/04
Veru Inc. Reports Earnings Results for the First Quarter Ended December 31, 2023	01/04
Veru Reschedules Annual Meeting of Shareholders	25/03
Veru Reschedules Annual Meeting of Shareholders	22/03
Certain Options of Veru Inc. are subject to a Lock-Up Agreement Ending on 13-MAR-2024.	13/03
Certain Common Stock of Veru Inc. are subject to a Lock-Up Agreement Ending on 13-MAR-2024.	13/03

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Veru Inc.

Actions

VERU

US92536C1036

Autres langues

Filtres